January 4, 2019
“Our investors have articulated that what will transform the potential of Halozyme is success in pancreas cancer,” CEO Helen Torley told the San Diego Business Journal in March.
Stories this photo appears in:
2019 Look Ahead: Health Care
San Diego’s Halozyme is headed for an inflection point. In the second half of the year, analysts expect key clinical trial data to be released on Halozyme’s pegph20 in metastatic pancreas cancer. The therapeutic candidate is in a late-stage trial, or known as phase 3.